Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 9
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Nielsen, R. E. Levander, S. Kjaersdam Telléus, G. Jensen, S. O. W. Østergaard Christensen, T. and Leucht, S. 2015. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatrica Scandinavica, Vol. 131, Issue. 3, p. 185.

    Bosia, Marta Zanoletti, Andrea Spangaro, Marco Buonocore, Mariachiara Bechi, Margherita Cocchi, Federica Pirovano, Adele Lorenzi, Cristina Bramanti, Placido Smeraldi, Enrico and Cavallaro, Roberto 2014. Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment. Psychiatry Research, Vol. 217, Issue. 1-2, p. 9.

    Müller, Mario Vetter, Stefan Weiser, Mark Frey, Franz Ajdacic-Gross, Vladeta Stieglitz, Rolf-Dieter and Rössler, Wulf 2013. Precursors of cognitive impairments in psychotic disorders: A population-based study. Psychiatry Research, Vol. 210, Issue. 1, p. 329.

    Hasan, Alkomiet Falkai, Peter Wobrock, Thomas Lieberman, Jeffrey Glenthoj, Birte Gattaz, Wagner F. Thibaut, Florence and Möller, Hans-Jürgen 2012. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry, Vol. 13, Issue. 5, p. 318.

    Stone, William S. Giuliano, Anthony J. Tsuang, Ming T. Braff, David L. Cadenhead, Kristin S. Calkins, Monica E. Dobie, Dorcas J. Faraone, Stephen V. Freedman, Robert Green, Michael F. Greenwood, Tiffany A. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Mintz, Jim Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Roe, Andrea H. Schork, Nicholas J. Siever, Larry J. Silverman, Jeremy M. Swerdlow, Neal R. Thomas, Alison R. Tsuang, Debby W. Turetsky, Bruce I. and Seidman, Larry J. 2011. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: Findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophrenia Research, Vol. 128, Issue. 1-3, p. 102.

    RÉMILLARD, SOPHIE POURCHER, EMMANUELLE and COHEN, HENRI 2010. Long-term skill proceduralization in schizophrenia. Journal of the International Neuropsychological Society, Vol. 16, Issue. 01, p. 148.

    Danielyan, Arman and Nasrallah, Henry A. 2009. Neurological Disorders in Schizophrenia. Psychiatric Clinics of North America, Vol. 32, Issue. 4, p. 719.

    Olivares, José M Rodriguez-Martinez, Alfonso Burón, José A Alonso-Escolano, David and Rodriguez-Morales, Alexander 2008. Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia. Applied Health Economics and Health Policy, Vol. 6, Issue. 1, p. 41.

    Olivares, Josè M. Rodriguez-Martinez, Alfonso Buron, Josè A. Alonso-Escolano, David and Rodriguez-Morales, Alexander 2008. Analisi costo-efficacia dello switch da un trattamento antipsicotico a risperidone iniettabile a rilascio prolungato in pazienti con schizofrenia. Giornale Italiano di Health Technology Assessment, Vol. 1, Issue. 1, p. 39.

  • Journal of the International Neuropsychological Society, Volume 14, Issue 1
  • January 2008, pp. 110-118

Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia

  • SOPHIE RÉMILLARD (a1), EMMANUELLE POURCHER (a2) (a3) and HENRI COHEN (a1) (a2) (a3)
  • DOI:
  • Published online: 14 December 2007

There is evidence in the literature that cognitive functions in schizophrenia (SC) may be improved by atypical neuroleptics (NLPs) in contrast to typical medication, but there is still controversy regarding this apparent superiority of atypical drugs. In this study, we assessed the differential effects of risperidone and haloperidol on verbal memory, attention, and psychiatric symptoms in SC. The performance of 28 SC participants, randomly assigned to risperidone (2–6 mg/day) or haloperidol (2–40 mg/day), was compared with that of healthy controls. The California Verbal Learning Test (CVLT), the d2 Cancellation Test, and the Positive and Negative Symptoms Scale were administered at baseline and 3, 6, and 12 months. Relative to controls, all SC participants showed markedly impaired verbal memory and processing speed at each assessment period. There was no differential effect between the two NLPs on CVLT and d2 performance. However, risperidone was more effective than haloperidol in reducing psychiatric symptoms. Improvement in symptom severity was not associated with improvement in neurocognitive performance on these specific tests. Neither conventional nor atypical neuroleptic medications improved neurocognitive functioning over a 12-month follow-up, suggesting that psychopathological improvement under risperidone is independent of cognitive function. (JINS, 2008, 14, 110–118.)

Corresponding author
Correspondence and reprint request to: Henri Cohen, Psychology and Cognitive Neuroscience Laboratory, Université Paris Descartes-CNRS, 71 Ave. Edouard-Vaillant, Boulogne-Billancourt 92774, France. E-mail:
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Journal of the International Neuropsychological Society
  • ISSN: 1355-6177
  • EISSN: 1469-7661
  • URL: /core/journals/journal-of-the-international-neuropsychological-society
Please enter your name
Please enter a valid email address
Who would you like to send this to? *